ACT Expands Embryonic Stem Cell Treatment for Stargardt’s to UK
September 26, 2011
Submit Comments
In a news announcement today, Advanced Cell Technology said it had received approval to expand its stem cell treatment for Stargardt’s Macular Dystrophy to Moorfield’s Hospital in the UK.
As reported by the press, doctors will be injecting retinal cells into the eyes of 12 patients with Stargardt’s macular dystrophy. The London trial will run alongside a similar study that began in July at the Jules Stein Eye Institute at the University of California, Los Angeles. To date, only one patient has been treated in the US trial for Stargardt’s disease. The results from both studies are expected next year.
For the rest of the story, follow this link.
Comments (0)
Trackbacks
Print this post
Filed in Clinical Trials, Industry News, Macular Degeneration, New Technologies, Research, Retina, Stem Cell Therapies
You might also enjoy...
- Using Stem Cells to Treat Dry AMD and Stargardt’s Macular Dystrophy
- Progress Made in Treating Stargardt’s and Dry AMD Using Embryonic Stem Cells
- First Clinical Results of Using Embryonic Stem Cells to Treat Eye Disease Published in The Lancet
- A Complete List of Current Ophthalmic Stem Cell Trials
- First Patients With Macular Degeneration and Stargardt’s Disease Receive Stem Cell Treatment
Comments
Jump down to form below to submit your own comments
